Skip to content
10-Q

Quarterly Report

Cadrenal Therapeutics, Inc. CVKD

0001213900-26-053074

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 6, 2026 2.87M sh
Shares Diluted Q1 2026 · Mar 31, 2026 2.41M sh
Shares Diluted Q1 2026 · Mar 31, 2025 1.84M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$4.65M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $2.31M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $4.01M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.8M
Stockholders Equity Q1 2026 · Dec 31, 2025 $2.74M
Stockholders Equity Q1 2026 · Mar 31, 2025 $6.11M
Stockholders Equity Q1 2026 · Dec 31, 2024 $7.44M
Current Liabilities Q1 2026 · Mar 31, 2026 $1.06M
Current Liabilities Q1 2026 · Dec 31, 2025 $1.59M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.06M
Total Liabilities Q1 2026 · Dec 31, 2025 $1.59M
Current Assets Q1 2026 · Mar 31, 2026 $2.86M
Current Assets Q1 2026 · Dec 31, 2025 $4.32M
Total Assets Q1 2026 · Mar 31, 2026 $2.86M
Total Assets Q1 2026 · Dec 31, 2025 $4.33M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.04
Eps Diluted Q1 2026 · Mar 31, 2025 −$2.09
Eps Basic Q1 2026 · Mar 31, 2026 −$1.04
Eps Basic Q1 2026 · Mar 31, 2025 −$2.09
Sga Expense Q1 2026 · Mar 31, 2026 $1.74M
Sga Expense Q1 2026 · Mar 31, 2025 $2.25M
Rd Expense Q1 2026 · Mar 31, 2026 $771.51K
Rd Expense Q1 2026 · Mar 31, 2025 $1.67M
Net Income Q1 2026 · Mar 31, 2026 −$2.5M
Net Income Q1 2026 · Mar 31, 2025 −$3.85M
Operating Income Q1 2026 · Mar 31, 2026 −$2.51M
Operating Income Q1 2026 · Mar 31, 2025 −$3.93M
Capex Q1 2026 · Mar 31, 2025 $3.25K